Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis

被引：76

作者：

Alffenaar, J. W. C. ^{[1
]}

van Altena, R. ^{[5
]}

Bokkerink, H. J. ^{[2
]}

Luijckx, G. J. ^{[2
]}

van Soolingen, D. ^{[6
]}

Aarnoutse, R. E. ^{[7
]}

van der Werf, T. S. ^{[3
,4
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Hosp & Clin Pharm, NL-9700 RB Groningen, Netherlands

[2] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands

[3] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, NL-9700 RB Groningen, Netherlands

[4] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis & TB, NL-9700 RB Groningen, Netherlands

[5] Univ Groningen, Univ Med Ctr Groningen, TB Ctr Beatrixoord, Haren, Netherlands

[6] Natl Inst Publ Hlth & Environm, Natl Mycobacteria Reference Lab, NL-3720 BA Bilthoven, Netherlands

[7] Radboud Univ Nijmegen, Med Ctr, Dept Clin Pharm, NL-6525 ED Nijmegen, Netherlands

来源：

CLINICAL INFECTIOUS DISEASES | 2009年 / 49卷 / 07期

关键词：

MYCOBACTERIUM-TUBERCULOSIS; IN-VITRO; PHARMACODYNAMICS; RESISTANCE;

D O I：

10.1086/605576

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Moxifloxacin cerebrospinal fluid (CSF) penetration was evaluated by obtaining full plasma and CSF time concentration curves for 4 patients with tuberculous meningitis. The geometric mean ratio of the areas under the curve for CSF to plasma were 0.82 (range, 0.70-0.94) at 400 mg once per day and 0.71 (0.58-0.84) at 800 mg once per day.

引用

页码：1080 / 1082

页数：3

共 14 条

[1] Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis [J].

Alffenaar, J. W. C. ;

de Vries, P. M. ;

Luijckx, G. J. ;

van Soolingen, D. ;

van der Werf, T. S. ;

van Altena, R. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (06) :2293-2295

[2] Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs [J].

Codecas, Luigi Ruffo ;

Ferrara, Giovanni ;

Ferrarese, Maurizio ;

Morandi, Maria Antonietta ;

Penati, Valeria ;

Lacchini, Carta ;

Vaccarino, Patrizia ;

Migliori, Giovanni Battista .

RESPIRATORY MEDICINE, 2006, 100 (09) :1566-1572

[3] Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects [J].

Démolis, JL ;

Kubitza, D ;

Tennezé, L ;

Funck-Brentano, C .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (06) :658-666

[4] Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling [J].

Gumbo, T ;

Louie, A ;

Deziel, MR ;

Parsons, LM ;

Salfinger, M ;

Drusano, GL .

JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (09) :1642-1651

[5] Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect [J].

Kanellakopoulou, Kyriaki ;

Pagoulatou, Alexandra ;

Stroumpoulis, Konstantinos ;

Vafiadou, Marianthi ;

Kranidioti, Hariklia ;

Giamarellou, Helen ;

Giamarellos-Bourboulis, Evangelos J. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (06) :1328-1331

[6] Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis [J].

Nijland, H. M. J. ;

Ruslami, R. ;

Suroto, A. Juwono ;

Burger, D. M. ;

Alisjahbana, B. ;

van Crevel, R. ;

Aarnoutse, R. E. .

CLINICAL INFECTIOUS DISEASES, 2007, 45 (08) :1001-1007

[7] Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections [J].

Nuermberger, E ;

Grosset, J .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (04) :243-255

[8]

Ostergaard C, 1998, ANTIMICROB AGENTS CH, V42, P1706

[9] In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis [J].

Rodríguez, JC ;

Ruiz, M ;

López, M ;

Royo, G .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (06) :464-467

[10] Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis [J].

Rodriguez-Cerrato, V ;

McCoig, CC ;

Michelow, IC ;

Ghaffar, F ;

Jafri, HS ;

Hardy, RD ;

Patel, C ;

Olsen, K ;

McCracken, GH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3092-3097

← 1 2 →